148 results on '"Philippe Bertheau"'
Search Results
2. Supplementary Figure Legend from Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–Mediated Lysis
- Author
-
Salem Chouaib, Fathia Mami-Chouaib, Jean Paul Thiery, Nicole Tsang Ying Hung, Joan Herr Keira, Tuan Zea Tan, Michèle Sabbah, Annette K. Larsen, Philippe Vielh, Cécile Badoual, Philippe Bertheau, Patricia De Cremoux, Fabrice André, Muhammad Zaeem Noman, Meriem Hasmim, Bassam Janji, and Intissar Akalay
- Abstract
PDF file - 108K
- Published
- 2023
3. Supplementary Data 3 from Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–Mediated Lysis
- Author
-
Salem Chouaib, Fathia Mami-Chouaib, Jean Paul Thiery, Nicole Tsang Ying Hung, Joan Herr Keira, Tuan Zea Tan, Michèle Sabbah, Annette K. Larsen, Philippe Vielh, Cécile Badoual, Philippe Bertheau, Patricia De Cremoux, Fabrice André, Muhammad Zaeem Noman, Meriem Hasmim, Bassam Janji, and Intissar Akalay
- Abstract
PDF file - 317K, List of EMT- and autophagy-related differentially expressed genes in SNAI1- and SNAI1-6SA-expressing MCF-7 cells
- Published
- 2023
4. Supplementary Data 1 from Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–Mediated Lysis
- Author
-
Salem Chouaib, Fathia Mami-Chouaib, Jean Paul Thiery, Nicole Tsang Ying Hung, Joan Herr Keira, Tuan Zea Tan, Michèle Sabbah, Annette K. Larsen, Philippe Vielh, Cécile Badoual, Philippe Bertheau, Patricia De Cremoux, Fabrice André, Muhammad Zaeem Noman, Meriem Hasmim, Bassam Janji, and Intissar Akalay
- Abstract
PDF file - 204K, Cancer stem cell properties of EMTed and autophagic cell lines
- Published
- 2023
5. Supplementary Data 5 from Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–Mediated Lysis
- Author
-
Salem Chouaib, Fathia Mami-Chouaib, Jean Paul Thiery, Nicole Tsang Ying Hung, Joan Herr Keira, Tuan Zea Tan, Michèle Sabbah, Annette K. Larsen, Philippe Vielh, Cécile Badoual, Philippe Bertheau, Patricia De Cremoux, Fabrice André, Muhammad Zaeem Noman, Meriem Hasmim, Bassam Janji, and Intissar Akalay
- Abstract
PDF file - 10396K, Human breast cancer biopsies were stained for SNAI2 and LC3B expression by immunohistochemistry on serial tumor sections
- Published
- 2023
6. Supplementary Data 2 from Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–Mediated Lysis
- Author
-
Salem Chouaib, Fathia Mami-Chouaib, Jean Paul Thiery, Nicole Tsang Ying Hung, Joan Herr Keira, Tuan Zea Tan, Michèle Sabbah, Annette K. Larsen, Philippe Vielh, Cécile Badoual, Philippe Bertheau, Patricia De Cremoux, Fabrice André, Muhammad Zaeem Noman, Meriem Hasmim, Bassam Janji, and Intissar Akalay
- Abstract
PDF file - 72K, SNAI1-6SA cells were sorted by flow cytometry (MoFlo� Astrios� - Beckman Coulter, Inc) based on their ALDH activity
- Published
- 2023
7. Supplementary Data 4 from Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–Mediated Lysis
- Author
-
Salem Chouaib, Fathia Mami-Chouaib, Jean Paul Thiery, Nicole Tsang Ying Hung, Joan Herr Keira, Tuan Zea Tan, Michèle Sabbah, Annette K. Larsen, Philippe Vielh, Cécile Badoual, Philippe Bertheau, Patricia De Cremoux, Fabrice André, Muhammad Zaeem Noman, Meriem Hasmim, Bassam Janji, and Intissar Akalay
- Abstract
PDF file - 160K, Data mining of microarray data showing the connections between EMT and autophagy-related genes
- Published
- 2023
8. External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification
- Author
-
A. Arjona-Sanchez, A. Martinez-López, M.T. Moreno-Montilla, J. Mulsow, P. Lozano-Lominchar, B. Martínez-Torres, B. Rau, E. Canbay, A. Sommariva, M. Milione, M. Deraco, O. Sgarbura, A. Torgunrud, V. Kepenekian, N.J. Carr, A. Hoorens, J.B. Delhorme, R. Wernert, D. Goere, L. Martin-Roman, S. Cosyns, K. Flatmark, B. Davidson, L. Khellaf, F. Pereira-Perez, L. Rodriguez-Ortiz, A. Ibáñez-Costa, A. Romero-Ruiz, B. Rufián-Andújar, F. Valenzuela-Molina, A. Casado-Adam, J.M. Sánchez-Hidalgo, S. Rufián- Peña, R. Ortega-Salas, M. Granados-Rodríguez, M.C. Vázquez-Borrego, F.I. Bura, J.P. Castaño, S. Kusamura, D. Baratti, M. Guaglio, Pascual A. Angel Castaño, Ruiz de Valbuena Bueno C, F. Quénet, S. Yilmaz, Torun B. Canbay, E. Sola Vendrell, L. González-Bayón, W. Ceelen, W. Willaert, J. Demuytere, M.E. Alberto-Vilchez, S. Gül-Klein, Glehen Olivier, Isabelle Bonnefoy, Cecile Odin, Laurent Villeneuve, Sylvie Isaac, Nazim Benzerdjeb, Juliette Fontaine, Philippe Bertheau, Maysoun Kassem, Isabelle Sourrouille, Maximiliano Gelli, Charles Honore, Peggy Dartigues, Valérie Boige, Véroniques Verriele, Cécile Brignad, Gerlinde Averous, C. Shields, J. Aird, Antonio Scapinello, Maria Chiara Biatta, Marco Tonello, and Chiara Cenzi
- Subjects
Oncology ,Surgery ,General Medicine - Published
- 2023
9. Une lésion labiale inhabituelle
- Author
-
Matthieu Chicaud, Frédéric Caux, Paul Tsianakas, Philippe Bertheau, and Jacqueline Rivet
- Subjects
Pathology and Forensic Medicine - Published
- 2023
10. Le premier data challenge organisé par la Société Française de Pathologie : une compétition internationale en 2020, un outil de recherche en intelligence artificielle pour l’avenir ?
- Author
-
Agathe Delaune, Séverine Valmary-Degano, Nicolas Loménie, Karim Zryouil, Nesrine Benyahia, Olivier Trassard, Virginie Eraville, Christine Bergeron, Mojgan Devouassoux-Shisheboran, Claire Glaser, Guillaume Bataillon, Emmanuel Bacry, Stéphanie Combes, Sophie Prevot, and Philippe Bertheau
- Subjects
Pathology and Forensic Medicine - Published
- 2022
11. Haemorrhagic shock secondary to a diffuse ulcerative enteritis after Ipilimumab and Nivolumab treatment for metastatic melanoma: a case report
- Author
-
Thomas Aparicio, Noémie Trystram, Pauline Laly, Barouyr Baroudjian, Philippe Bertheau, and Jean-Marc Gornet
- Subjects
Advanced and Specialized Nursing ,Enteroscopy ,Enterocolitis ,medicine.medical_specialty ,business.industry ,Ipilimumab ,medicine.disease ,Gastroenterology ,Infliximab ,Enteritis ,03 medical and health sciences ,0302 clinical medicine ,Anesthesiology and Pain Medicine ,030220 oncology & carcinogenesis ,Internal medicine ,Medicine ,030211 gastroenterology & hepatology ,Ileitis ,Nivolumab ,medicine.symptom ,Colitis ,business ,medicine.drug - Abstract
We provide a unique case of haemorrhagic shock complicating a corticosteroid-resistant diffuse ulcerative enteritis in a patient treated with a combination of an anti CTLA-4 and an anti PD-1 for metastatic melanoma. Immunotherapy has changed the perspective for the management of patients with metastatic melanoma but are also responsible for digestive complications mainly represented by immunomediated colitis. Digestive bleeding is common in patients with extensive colonic lesions but has never been described in enteritis independent of colitis. The patient with acute intestinal obstruction related ileitis without evidence of stricture on imaging and then had a gastro-intestinal bleed. In the absence of haemorrhagic lesions on upper gastrointestinal endoscopy, colonoscopy and CT angiography, a surgical exploration with enteroscopy was performed. This revealed an extensive ulcerated jejunoileitis, with active bleeding, within a Meckel's diverticulum. Management included resection of the Meckel diverticulum with a transient double barrel ileostomy. Two infliximab infusions were given due to persistent bleeding. We observed a dramatic improvement after infliximab treatment with complete cessation of bleeding and no further need for transfusions. A complete mucosal healing has been achieved on enteroscopy at 3 months with disappearance of histological inflammatory lesions. This observation suggests that infliximab represents a therapeutic option in severe enteritis and may be as effective as in more moderate immune-mediated enterocolitis.
- Published
- 2022
12. Can AI predict epithelial lesion categories via automated analysis of cervical biopsies: The TissueNet challenge?
- Author
-
Nicolas Loménie, Capucine Bertrand, Rutger H.J. Fick, Saima Ben Hadj, Brice Tayart, Cyprien Tilmant, Isabelle Farré, Soufiane Z. Azdad, Samy Dahmani, Gilles Dequen, Ming Feng, Kele Xu, Zimu Li, Sophie Prevot, Christine Bergeron, Guillaume Bataillon, Mojgan Devouassoux-Shisheboran, Claire Glaser, Agathe Delaune, Séverine Valmary-Degano, Philippe Bertheau, Laboratoire d'Informatique Paris Descartes (LIPADE (URP_2517)), Université Paris Cité (UPCité), Morphologie et Images (MORPHEME), Inria Sophia Antipolis - Méditerranée (CRISAM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Institut de Biologie Valrose (IBV), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Signal, Images et Systèmes (Laboratoire I3S - SIS), Laboratoire d'Informatique, Signaux, et Systèmes de Sophia Antipolis (I3S), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Laboratoire d'Informatique, Signaux, et Systèmes de Sophia Antipolis (I3S), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Modélisation, Information et Systèmes - UR UPJV 4290 (MIS), Université de Picardie Jules Verne (UPJV), CSIRO Indian Ocean Marine Research Centre [Australia], The University of Western Australia (UWA), Centre for Southern Hemisphere Oceans Research, Hobart, Tasmania, Australia, Institut Langevin - Ondes et Images (UMR7587) (IL), Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Yangtze Delta Region Institute of Tsinghua University [Zhejiang], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Laboratoire CERBA [Saint Ouen l'Aumône], Institut Curie [Paris], Hospices Civils de Lyon (HCL), Université de Lyon - UDL, GenoSplice [Paris], Service d'Anatomie pathologique [CHRU Besançon], and Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
- Subjects
Artificial intelligence ,[SDV]Life Sciences [q-bio] ,Data challenge ,Uterine cervix ,Whole slide images ,Health Informatics ,Computer Science Applications ,Pathology and Forensic Medicine ,[INFO.INFO-AI]Computer Science [cs]/Artificial Intelligence [cs.AI] - Abstract
The French Society of Pathology (SFP) organized its first data challenge in 2020 with the help of the Health Data Hub (HDH). The organization of this event first consisted of recruiting nearly 5000 cervical biopsy slides obtained from 20 pathology centers. After ensuring that patients did not refuse to include their slides in the project, the slides were anonymized, digitized, and annotated by expert pathologists, and finally uploaded to a data challenge platform for competitors from around the world. Competing teams had to develop algorithms that could distinguish 4 diagnostic classes in cervical epithelial lesions. Among the many submissions from competitors, the best algorithms achieved an overall score close to 95%. The final part of the competition lasted only 6 weeks, and the goal of SFP and HDH is now to allow for the collection to be published in open access for the scientific community. In this report, we have performed a "post-competition analysis" of the results. We first described the algorithmic pipelines of 3 top competitors. We then analyzed several difficult cases that even the top competitors could not predict correctly. A medical committee of several expert pathologists looked for possible explanations for these erroneous results by reviewing the images, and we present their findings here targeted for a large audience of pathologists and data scientists in the field of digital pathology.
- Published
- 2022
13. A massive open online course to teach undergraduate medical students in oncology: keys of success
- Author
-
Diaddin Hamdan, Frédéric Pamoukdjian, Jaqueline Lehmann-Che, Cédric de Bazelaire, Laetitia Vercellino, Julien Calvani, Maxime Battistella, Philippe Bertheau, Géraldine Falgarone, and Guilhem Bousquet
- Subjects
Multidisciplinary - Abstract
Massive Open Online Courses (MOOCs) are gaining popularity in education while classroom lectures are being deserted, especially after COVID-19 pandemic. Their added value in teaching undergraduate medical students remains to be confirmed. This study evaluated a MOOC devoted to undergraduate medical students in a blended oncology-teaching university program. It was the first to target undergraduate medical students in oncology at its beginning. Students were asked to participate in a survey before and after MOOC to explore interactions between their characteristics and final grades, 65% of the participating students belonged to the rich class. 70% of the students completed the MOOC. Grades distributions were similar before and after MOOC implementation, so MOOC doesn't alter overall results. In addition, there was a positive effect of the MOOC on median grades on the immediate test. The univariate and multivariate analysis showed that socioeconomic status and student's willingness to participate interacted significantly with final results. Particularly, students' motivation and satisfaction were associated with better results; Almost 70% of students asked for blended learning. E-learning is reliable to teach oncology to undergraduate medical students. The success is directly linked to students' willingness to participate, and can be improved using blended methods including tutorials.
- Published
- 2022
14. Une complication digestive rare sous anti-PD-1 (pembrolizumab)
- Author
-
Jean-Marc Gornet, Maxime Battistella, Julien Calvani, Justine Vivier-Chicoteau, Barouyr Baroudjian, Céleste Lebbé, Julie Delyon, Philippe Bertheau, and Rémie Elia
- Subjects
0301 basic medicine ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Pathology and Forensic Medicine - Abstract
Resume Le type de colite le plus frequemment observe sous immunotherapie anti-PD-1 est celui d’une colite aigue active a polynucleaires neutrophiles. A l’inverse, la colite collagene, qui appartient a la famille des colites microscopiques, est exceptionnelle. Nous rapportons un cas de colite collagene chez un homme de 76 ans, traite par pembrolizumab pour un melanome cutane multimetastatique. Quatorze mois apres l’introduction du pembrolizumab, le patient a developpe une diarrhee de grade 3 (jusqu’a 9 selles liquides non glairo-sanglantes/j), associee a une profonde hypokaliemie. Aucun agent infectieux n’a ete identifie. La rectosigmoidoscopie a mis en evidence une congestion colique diffuse, sans ulceration. Les biopsies coliques systematiques ont revele un epaississement de la bande collagene sous-epitheliale, mesurant entre 20 et 30 μm d’epaisseur, associe a une augmentation moderee de la cellularite inflammatoire du chorion, avec presence de lymphocytes et plasmocytes. Le patient a ete efficacement traite par un arret temporaire du pembrolizumab et la mise en place d’une corticotherapie (prednisone) a la dose de 0,8 mg/kg/j, d’abord intraveineuse, puis par voie orale, avec decroissance progressive sur 6 semaines. Lors de la decroissance de la prednisone, une recidive des diarrhees a ete observee. Il a donc ete propose un relais par budesonide 9 mg/j permettant une resolution complete et definitive des diarrhees. Le budesonide a depuis ete stoppe. Le pembrolizumab n’a pour l’instant pas ete repris. Il existe actuellement une progression osseuse localisee du melanome, traitee par radiotherapie seule. En cas de reprise evolutive plus importante, un nouveau traitement systemique pourra etre discute.
- Published
- 2020
15. Ganglioneuromatose du tube digestif dans le cadre d’une neurofibromatose de type 1
- Author
-
Alice Kieny, Claire Auzolle, Philippe Bertheau, and Maxime Battistella
- Subjects
0301 basic medicine ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Pathology and Forensic Medicine - Abstract
Resume La ganglioneuromatose du tube digestif est une affection rare pouvant etre isolee ou syndromique. Une neoplasie endocrinienne multiple de type 2 est le syndrome le plus frequemment associe. De plus rares cas d’association avec la neurofibromatose de type 1 ont egalement ete decrits. Nous rapportons un patient ayant une neurofibromatose de type 1 et une ganglioneuromatose du colon decouverte fortuitement a la suite de troubles digestifs.
- Published
- 2019
16. [The first data challenge of the french society of pathology: An international competition in 2020, a research tool in A.I. for the future?]
- Author
-
Agathe, Delaune, Séverine, Valmary-Degano, Nicolas, Loménie, Karim, Zryouil, Nesrine, Benyahia, Olivier, Trassard, Virginie, Eraville, Christine, Bergeron, Mojgan, Devouassoux-Shisheboran, Claire, Glaser, Guillaume, Bataillon, Emmanuel, Bacry, Stéphanie, Combes, Sophie, Prevot, and Philippe, Bertheau
- Subjects
Pathologists ,Artificial Intelligence ,Biopsy ,Humans ,Female ,Cervix Uteri ,Algorithms - Abstract
The french society of pathology (SFP) organized in 2020 its first data challenge with the help of Health Data Hub (HDH). The organisation of this event first consisted in recruiting almost 5000 slides of uterus cervical biopsies obtained in 20 pathology centers. After having made sure that patients did not refuse to include their slides in the project, the slides were anonymised, digitized and annotated by expert pathologists, and were finally uploaded on a data challenge platform for competitors all around the world. Competitors teams had to develop algorithms that could distinguish among four diagnostic classes in epithelial lesions of uterine cervix. Among many submissions by competitors, the best algorithms obtained an overall score close to 95%. The best 3 teams shared 25k€ prizes during a special session organised during the national congress of the SFP. The final part of the competition lasted only 6 weeks and the goal of SFP and HDH is now to allow for the collection to be published in open access. This final step will allow data scientists and pathologists to further develop artificial intelligence algorithms in this medical area.
- Published
- 2021
17. Le compte rendu augmenté comme réponse à la Grande Dépression en ACP. Impulsion, une offre de New Deal pour l’ACP
- Author
-
Jean-Pierre Bellocq and Philippe Bertheau
- Subjects
Political science ,Humanities ,Pathology and Forensic Medicine - Published
- 2019
18. Métastase mammaire d’un carcinome médullaire thyroïdien : un challenge diagnostique
- Author
-
Philippe Bertheau, Charlotte Gardair, Laurence Cahen-Doidy, Patrick Charveriat, Philippe Drabent, Anne de Roquancourt, Université Paris Diderot - Paris 7 (UPD7), Service d'anatomie et cytologie pathologiques, Université de Paris (UP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hopital Saint-Louis [AP-HP] (AP-HP), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Subjects
0301 basic medicine ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,[SDV]Life Sciences [q-bio] ,030220 oncology & carcinogenesis ,Pathology and Forensic Medicine - Abstract
Resume La reconnaissance des metastases mammaires par le pathologiste est fondamentale car leur pronostic et leur traitement sont differents de ceux des carcinomes mammaires primitifs. Nous rapportons l’observation d’une patiente de 54 ans presentant sur sa mammographie de depistage un nodule du sein gauche connu depuis 5 ans ayant discretement augmente de taille. L’echographie mammaire montrait une formation nodulaire hypoechogene reguliere de 1,2 cm. Une microbiopsie a ete effectuee. A l’examen microscopique, on observait une proliferation tumorale realisant des massifs au sein d’un stroma peu abondant richement vascularise. Les cellules tumorales avaient un cytoplasme moyennement abondant, eosinophile, granuleux et un noyau arrondi, legerement atypique. Une mitose a ete retrouvee en moyenne pour 10 champs au grossissement × 400. Les cellules tumorales n’exprimaient pas les recepteurs hormonaux mais la chromogranine A, la synaptophysine, le TTF1 et la thyrocalcitonine. L’index de proliferation etabli par l’anticorps anti-Ki67 etait de 5 %. Le diagnostic retenu etait celui de localisation secondaire d’une tumeur neuroendocrine bien differenciee, dont le profil immunohistochimique oriente en premier lieu vers une origine thyroidienne. Nous avons appris, ulterieurement, que la patiente avait un antecedent de thyroidectomie totale 13 ans auparavant. Il s’agissait d’un carcinome medullaire de la thyroide sporadique. Dans le cadre du bilan d’extension, la scintigraphie osseuse a mis en evidence une lesion lacunaire de la partie posterieure de l’aile iliaque droite suspecte de localisation secondaire. Cette lesion iliaque droite a ete biopsiee. Il s’agissait egalement d’une localisation du carcinome medullaire thyroidien connu. Le diagnostic final est celui de carcinome medullaire thyroidien metastatique, lentement evolutif, la metastase mammaire existant probablement depuis 5 ans.
- Published
- 2019
19. Multimodal machine learning model prediction of complete pathological response to neoadjuvant chemotherapy in triple-negative breast cancer
- Author
-
David Groheux, Loïc Ferrer, Jennifer Vargas, Antoine Martineau, Luis Teixeira, Philippe Menu, Philippe Bertheau, Olivier Gallinato, Thierry Colin, and Jacqueline Lehmann-Che
- Subjects
Cancer Research ,Oncology - Abstract
601 Background: Triple negative breast cancer (TNBC) is a biologically and clinically heterogenous disease, associated with poorer outcomes when compared with other subtypes of breast cancer. In early-stage TNBC, surgery with curative intent remains the mainstay of therapy. Neoadjuvant chemotherapy is often given prior to surgery and achieving pathological complete response (pCR) has been associated with improved long-term outcomes in terms of progression-free survival (PFS) and overall survival (OS). There is thus high clinical interest in the ability to accurately predict pCR status using baseline data. Methods: A retrospective cohort of 57 patients with early-stage TNBC treated with neoadjuvant chemotherapy was analyzed to develop a machine learning-based algorithm predictive of pCR likelihood at the individual patient level. Multimodal baseline data were collected including clinical, biological (e.g., histology, genomic profile including CDC2, CDC20, KPNA2, MYBL2, complete blood count, Ki67), imaging data (baseline PET/CT scan), the radiology report and clinical outcomes data (pCR, PFS, OS). For each patient, tumors were segmented in 3D by an experimented nuclear physician using the SOPHiA Radiomics platform. Radiomics features were then extracted following the IBSI standards and then combined with the other data modalities. A filter-based variable selection method was applied before training several machine learning algorithms. The optimization criterion was the Area Under the ROC Curve (AUC). Due to the small size of the cohort, a nested leave-pair-out cross-validation approach was used to properly estimate the model performance. Results: The best result was obtained with the SVM algorithm with a linear kernel, reaching an AUC of 0.82, a precision of 71%, a sensitivity of 71% and a specificity of 70%. The features with highest weight in the algorithm were a mix of radiological, radiomics, biological and clinical features, highlighting the importance of a truly multimodal analysis. Indeed, withdrawing a specific data modality (e.g., radiomics features or biological features), led to a decrease of ̃10% of the AUC. Patients were then stratified into two groups based upon their predicted pCR status. These two groups displayed a statistically significant difference in PFS (p
- Published
- 2022
20. Utility and Safety of Liver Biopsy in Patients with Undetermined Liver Blood Test Anomalies after Allogeneic Hematopoietic Stem Cell Transplantation: A Monocentric Retrospective Cohort Study
- Author
-
Alban Villate, Philippe Bertheau, Mathilde Ruggiu, Régis Peffault de Latour, Aurélie Plessier, Simona Pagliuca, Pierre-Emmanuel Rautou, David Michonneau, Gérard Socié, Pierre Bedossa, Flore Sicre de Fontbrune, Aliénor Xhaard, and Marie Robin
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Biopsy ,medicine.medical_treatment ,Hematopoietic stem cell transplantation ,Gastroenterology ,Cohort Studies ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Liver Function Tests ,Internal medicine ,Humans ,Transplantation, Homologous ,Medicine ,Blood test ,Child ,Aged ,Retrospective Studies ,Liver injury ,Transplantation ,medicine.diagnostic_test ,business.industry ,Hematopoietic Stem Cell Transplantation ,Retrospective cohort study ,Hematology ,Middle Aged ,medicine.disease ,Liver ,030220 oncology & carcinogenesis ,Liver biopsy ,Female ,030211 gastroenterology & hepatology ,Differential diagnosis ,business ,Viral hepatitis - Abstract
Liver blood test anomalies are common after allogeneic hematopoietic stem cell transplantation (allo-HSCT), but their cause often remains difficult to identify. Our objective was to evaluate the safety and utility of liver biopsies in patients who underwent allo-HSCT. In a retrospective single-center cohort study, we reviewed all cases of patients who underwent liver biopsy between June 2005 and July 2017. During this period, 54 biopsies were performed in 45 patients, in which 38 patients underwent allo-HSCT for malignant and 7 for nonmalignant hematological disorders. Median time between allo-HSCT and liver biopsy was 213 days. Seven biopsies were percutaneous, and 47 were transjugular. No adverse event related to the biopsy procedure occurred; 94.5% biopsies (51 of 54) led to a histological diagnosis. Cholestatic graft-versus-host disease was histologically demonstrated in 16 biopsies (30%); hepatitis-like graft-versus-host disease in 9 biopsies (17%); nonalcoholic steatohepatitis in 6 biopsies (9%); regenerative nodular hyperplasia in 4 biopsies (5%); and drug-induced liver injury, sinusoidal obstruction syndrome, and viral hepatitis each in 3 biopsies (5%). Association between clinical, laboratory, imaging and pathological features was poor. Only 34% of physicians' prebiopsy hypotheses were confirmed by pathological findings. Patient management was influenced by liver biopsy results in 65% of cases, allowing us to identify a new diagnosis (n = 13), rule out a differential diagnosis (n = 14), or confirm the main hypothesis (n = 6). In conclusion, liver biopsy is a safe and useful technique to investigate liver blood test anomalies following allo-HSCT.
- Published
- 2018
21. Prevalence and prognosis of microsatellite instability in oesogastric adenocarcinoma, NORDICAP 16-01
- Author
-
Gael Goujon, Nathalie Théou-Anton, Nicolas Poté, My-Linh Tran-Minh, Philippe Bertheau, Marie Dior, Nahla Cucherousset, Charlotte Gardair, for Nordicap, Rachid Kaci, Olivier Schischmanoff, Anne Couvelard, Florence Mary, Thomas Aparicio, Jérôme Lambert, and Jacqueline Lehmann-Che
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Adenocarcinoma ,MLH1 ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Stomach Neoplasms ,Internal medicine ,medicine ,Prevalence ,Humans ,In patient ,Cumulative incidence ,neoplasms ,Genotyping ,Retrospective Studies ,Hepatology ,business.industry ,nutritional and metabolic diseases ,Microsatellite instability ,medicine.disease ,Prognosis ,digestive system diseases ,Multicenter study ,030220 oncology & carcinogenesis ,DNA methylation ,030211 gastroenterology & hepatology ,Microsatellite Instability ,business ,MutL Protein Homolog 1 - Abstract
Background The prevalence and prognosis association of microsatellite instability (MSI) in oesogastric junction and gastric adenocarcinoma (OGC) have been reported with conflicting results. Methods Patients with OGC from 2010 to 2015 were enrolled in this retrospective multicenter study. MSI was determined by genotyping. MLH1 promoter methylation and BRAF V600E mutation were screened in the MSI tumors. Results Among 315 tumors analyzed, 39 (12.4%) were of the MSI phenotype. Compared to MSS tumors, MSI tumors were more frequent in patients > 70 years (17% vs 9%, p = 0.048) and in gastric antral primary (20% versus 5% in junction tumor and 12% in fundus tumor. Among 29 MSI tumors analyzed, 28 had a loss of MLH1 protein expression and 27 had MLH1 promotor hypermethylation. None had a BRAF V600E mutation. The 4-year cumulative incidence of recurrence for patients with resected tumor was significantly lower in dMMR tumors versus pMMR tumors (17% versus 47%, p = 0.01). For the patients with unresectable tumor the median overall survival was 11 months in MSS group and 14 months in MSI group (p = 0.24). Conclusion MSI prevalence in OGC was 12.4%, associated with antral localization and advanced age. Patients with MSI tumors had a lower cumulative incidence of recurrence after surgery. MSI phenotype was mainly associated with loss of MLH1 protein expression, MLH1 promotor hypermethylation and had no BRAF V600E mutation.
- Published
- 2020
22. 18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients
- Author
-
Philippe Bertheau, Lucie Biard, Brigitte Poirot, Christos Sotiriou, Luis Augusto Teixeira, Jacqueline Lehmann-Che, Matthieu Resche-Rigon, Patricia de Cremoux, Pascal Merlet, Fatiha Bouhidel, David Groheux, and Marc Espié
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,18FDG-PET/CT ,Neoadjuvant chemotherapy ,03 medical and health sciences ,Breast cancer ,0302 clinical medicine ,breast cancer ,Internal medicine ,Biopsy ,medicine ,TP53 status ,Chemotherapy ,Pathological complete response ,medicine.diagnostic_test ,business.industry ,Surrogate endpoint ,HER2 negative ,medicine.disease ,3. Good health ,030104 developmental biology ,Real-time polymerase chain reaction ,Positron emission tomography ,030220 oncology & carcinogenesis ,pathological complete response ,Fdg pet ct ,business ,Psychiatrie ,Research Paper ,neoadjuvant chemotherapy - Abstract
Background: The efficacy of neoadjuvant chemotherapy regimens in advanced luminal breast cancer patients is difficult to predict. Intrinsic properties of breast tumors, including altered gene expression profile and dynamic evaluation of metabolic properties of tumor cells using positron emission tomography/computed tomography (PET/CT) of tumor cells, have been identified to guide patient's prognosis. The aim of this study is to determine if both analyses may improve the prediction of response to neoadjuvant chemotherapy in ER-positive / HER2-negative breast cancers (BCs) patients. Methods: We used metabolic PET parameters, at diagnosis and after two cycles of chemotherapy and proliferation gene expression profile on biopsy at diagnosis, in particular, the genomic grade index (GGI) analyzed by reverse transcription and quantitative polymerase chain reaction (RT-qPCR). The pathological response was the surrogate endpoint. Results: The change of FDG uptake between baseline PET and interim PET after 2 cycles of neoadjuvant chemotherapy (ΔSUVmax) was highly associated with pCR (p=0.008). We also observed an ability of P53 mutated status (p=0.042), in addition to histological grade (p=0. 0004), and PR expression (p=0.01) to predict pCR in ERpositive BCs, whereas no proliferation marker predicted pCR (P=0.39 for GGI). Finally, only ΔSUVmax was significantly associated with event free survival (p=0.047). Conclusions: Our results confirm the predictive and prognostic value of tumor ΔSUVmax in ER-positive /HER2-negative advanced BCs patients. These findings can be helpful to select high-risk patients within trials investigating novel treatment strategies., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2018
23. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency
- Author
-
Rachid Kaci, Magali Svrcek, Dewi Vernerey, Pascale Cervera, Alex Duval, Philippe Bertheau, Yann Parc, Sylvie Dumont, Thierry André, Frédéric Bibeau, Romain Cohen, Daniel Lopez-Trabada, Jean-Marc Gornet, J-B. Bachet, Armelle Bardier, Elisabeth Hain, Olivier Buhard, Florence Renaud, Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 (UPMC), Service de Pathologie [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'hépato-gastroentérologie, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Gustave Roussy (IGR), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U1172 Inserm - U837 (JPArc), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Lille Nord de France (COMUE)-Université de Lille, UNICANCER - Institut régional du Cancer Montpellier Val d'Aurelle (ICM), CRLCC Val d'Aurelle - Paul Lamarque, Service de chirurgie générale et digestive [CHU Saint-Antoine], Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service d'Oncologie Médicale [CHU Saint -Antoine], Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 (JPArc), Université Lille Nord de France (COMUE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC), HAL-UPMC, Gestionnaire, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Service d'Oncologie Médicale [CHU Saint-Antoine]
- Subjects
Male ,0301 basic medicine ,Cancer Research ,Heredity ,Time Factors ,Colorectal cancer ,Kaplan-Meier Estimate ,DNA Mismatch Repair ,0302 clinical medicine ,Risk Factors ,PMS2 ,Neoplasm Metastasis ,Middle Aged ,Lynch syndrome ,Pedigree ,3. Good health ,Phenotype ,Treatment Outcome ,Molecular Diagnostic Techniques ,Oncology ,030220 oncology & carcinogenesis ,Female ,Microsatellite Instability ,DNA mismatch repair ,France ,Colorectal Neoplasms ,MutL Protein Homolog 1 ,Adult ,Proto-Oncogene Proteins B-raf ,congenital, hereditary, and neonatal diseases and abnormalities ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Biology ,MLH1 ,Disease-Free Survival ,Diagnosis, Differential ,03 medical and health sciences ,Germline mutation ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Predictive Value of Tests ,Biomarkers, Tumor ,medicine ,Humans ,Genetic Predisposition to Disease ,neoplasms ,Aged ,Proportional Hazards Models ,Retrospective Studies ,nutritional and metabolic diseases ,Cancer ,Microsatellite instability ,[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,DNA Methylation ,medicine.disease ,Colorectal Neoplasms, Hereditary Nonpolyposis ,[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,digestive system diseases ,030104 developmental biology ,Multivariate Analysis ,Mutation ,Cancer research - Abstract
International audience; Background: Patients treated with chemotherapy for microsatellite unstable (MSI) and/or mismatch repair deficient (dMMR) cancer metastatic colorectal cancer (mCRC) exhibit poor prognosis. We aimed to evaluate the relevance of distinguishing sporadic from Lynch syndrome (LS)-like mCRCs.Patients and methods: MSI/dMMR mCRC patients were retrospectively identified in six French hospitals. Tumour samples were screened for MSI, dMMR, RAS/RAF mutations and MLH1 methylation. Sporadic cases were molecularly defined as those displaying MLH1/PMS2 loss of expression with BRAFV600E and/or MLH1 hypermethylation and no MMR germline mutation.Results: Among 129 MSI/dMMR mCRC patients, 81 (63%) were LS-like and 48 (31%) had sporadic tumours; 22% of MLH1/PMS2-negative mCRCs would have been misclassified using an algorithm based on local medical records (age, Amsterdam II criteria, BRAF and MMR statuses when locally tested), compared to a systematical assessment of MMR, BRAF and MLH1 methylation statuses. In univariate analysis, parameters associated with better overall survival were age (P < 0.0001), metastatic resection (P = 0.001) and LS-like mCRC (P = 0.01), but not BRAFV600E. In multivariate analysis, age (hazard ratio (HR) = 3.19, P = 0.01) and metastatic resection (HR = 4.2, P = 0.001) were associated with overall survival, but not LS. LS-like patients were associated with more frequent liver involvement, metastatic resection and better disease-free survival after metastasectomy (HR = 0.28, P = 0.01). Median progression-free survival of first-line chemotherapy was similar between the two groups (4.2 and 4.2 months; P = 0.44).Conclusions: LS-like and sporadic MSI/dMMR mCRCs display distinct natural histories. MMR, BRAF mutation and MLH1 methylation testing should be mandatory to differentiate LS-like and sporadic MSI/dMMR mCRC, to determine in particular whether immune checkpoint inhibitors efficacy differs in these two populations.
- Published
- 2017
24. Angiosarcome épithélioïde surrénalien primitif simulant un carcinome peu différencié
- Author
-
Yaëlle Harrar, Maxime Battistella, Philippe Bertheau, Fatiha Bouhidel, Samira Miladi, Brigitte Roche, and Véronique Meignin
- Subjects
Pathology ,medicine.medical_specialty ,business.industry ,Anemia ,Epithelioid Angiosarcoma ,Tumor cells ,medicine.disease ,Pathology and Forensic Medicine ,Metastatic carcinoma ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Histological diagnosis ,medicine ,Immunohistochemistry ,Tumor surgery ,medicine.symptom ,business ,Confusion - Abstract
The adrenal primary epithelioid angiosarcoma (ASE) is a rare malignant tumor which can be histologically confused with other neoplasms. We report one case in a 79-year-old man who underwent adrenal tumor surgery for a mass fortuitly discovered by imaging for examination of an inflammatory syndrome associated with anemia. The histological diagnosis was difficult because of the undifferentiated and epithelioid appearance of tumor cells, whose immunohistochemical epithelial markers positivity led to frequent confusion with a metastatic carcinoma. Careful research for vascular differentiation at histopathological study and expression of immunohistochimical endothelial markers, are crucial to confirm the diagnosis.
- Published
- 2017
25. Massive open online course (MOOC) sur le diagnostic des cancers : bilan et évaluation de l’impact sur la perception de l’anatomie et cytologie pathologiques
- Author
-
Maxime Battistella, Cédric de Bazelaire, Yohann Pottier, Jeanne Tran Van Nhieu, Jocelyne Gervais, Emilie Moenaert, Patricia de Cremoux, Thierry Jo Molina, Laurent Prévaut, Karima Sekri, Julien Calvani, Marie Sockeel, Charlotte Gardair, Guilhem Bousquet, Philippe Bertheau, Jaqueline Lehmann-Che, and Michel Peuchmaur
- Subjects
03 medical and health sciences ,Medical education ,0302 clinical medicine ,020205 medical informatics ,Massive open online course ,0202 electrical engineering, electronic engineering, information engineering ,Teaching program ,030212 general & internal medicine ,02 engineering and technology ,Pathology and Forensic Medicine - Abstract
The Massive Open Online Course (or MOOC) "Diagnostic Strategies Cancers", was hosted in autumn 2016 on the platform "France Universite Numerique" and had two levels of learners: students in the field of health and biology and the general public. Of the 5285 learners in 81 different countries, 1237 (23%) were successfully certified. This MOOC was also integrated into the teaching program of medical students of Paris Diderot University and Paris 13 University. Using anonymous questionnaires before and after MOOC, it has been shown that pathology is less known than other medical specialties. Participation in this MOOC led to a marked improvement in participants' knowledge of the place and role of the pathologist in the diagnosis of cancers. Regarding the students who have followed the MOOC as part of their university course, their comments were very positive, but it is necessary to make substantial adjustments in the amounts and contents of the campus-based courses.
- Published
- 2017
26. [An unusual digestive complication under anti-PD-1 (pembrolizumab)]
- Author
-
Julien, Calvani, Rémie, Elia, Maxime, Battistella, Julie, Delyon, Justine, Vivier-Chicoteau, Jean-Marc, Gornet, Céleste, Lebbé, Barouyr, Baroudjian, and Philippe, Bertheau
- Subjects
Diarrhea ,Male ,Skin Neoplasms ,Colitis, Collagenous ,Humans ,Prednisone ,Hypokalemia ,Antibodies, Monoclonal, Humanized ,Budesonide ,Melanoma ,Aged - Abstract
The most commonly reported pattern of anti-PD-1 induced colitis is an active colitis characterized by neutrophilic inflammation and prominent apoptosis. On the other hand, reports of collagenous colitis (which is a microscopic colitis) are exceptional. In this report, we describe an unusual case of anti-PD1-associated collagenous colitis in a 76-year-old man, treated with pembrolizumab for a stage IV cutaneous melanoma. Fourteen months after the start of pembrolizumab, the patient developed a grade 3 diarrhea (up to 9 stools per day) associated with profound hypokalemia. No bacterial, viral or parasitological infectious agents were found from stool analysis. The rectosigmoidoscopy showed colonic diffuse congestion with no ulceration. Systematic biopsies were performed during endoscopy. Histologically, the fragments analyzed revealed a moderately thickened subepithelial collagen layer (20-30μm thick) associated with a mild mixed inflammatory infiltrate within the lamina propria. There were no granuloma lesions, ulcerations or viral inclusion bodies. The patient was initially successfully treated with corticosteroids (prednisone) and temporary interruption of pembrolizumab. However, during corticosteroids tapering, a relapse was observed. The treatment was switched to budesonide, leading to a complete and definitive resolution of diarrhea. To date, budesonide has been stopped and pembrolizumab has not been restarted. Currently, there is a bone progression treated by radiotherapy alone. In case of a more important progression, a systemic treatment will be secondarily discussed.
- Published
- 2019
27. Severe gastrointestinal toxicity of MEK inhibitors
- Author
-
Philippe Bertheau, Cécile Pagès, Céleste Lebbé, Nelson Lourenco, Nadim Mourad, Julie Delyon, Matthieu Allez, Clara Allayous, A. Ballon, Barouyr Baroudjian, and Pirayeh Eftekhari
- Subjects
0301 basic medicine ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Skin Neoplasms ,Databases, Factual ,Nausea ,Pyridones ,MAP Kinase Kinase 1 ,Antineoplastic Agents ,Dermatology ,Pyrimidinones ,Gastroenterology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Piperidines ,Gastrointestinal perforation ,Internal medicine ,Medicine ,Humans ,Enzyme Inhibitors ,Adverse effect ,Melanoma ,Aged ,Retrospective Studies ,Trametinib ,Cobimetinib ,business.industry ,Binimetinib ,Middle Aged ,medicine.disease ,Discontinuation ,Gastrointestinal Tract ,030104 developmental biology ,Treatment Outcome ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Vomiting ,Azetidines ,Benzimidazoles ,Female ,medicine.symptom ,business - Abstract
Gastrointestinal toxicities of MEK inhibitors in melanoma patients are frequent. In clinical trials, the most common digestive adverse events were nausea, vomiting, and diarrhoea. However, severe toxicities such as colitis and gastrointestinal perforation, some with fatal outcomes, have been reported. These rare but severe adverse events are not well described. We performed a retrospective analysis of all patients with stage IV and unresectable stage III melanoma treated with a MEK inhibitors at Saint-Louis Hospital, Paris, between 1 August 2013 and 15 October 2018. Among 119 patients exposed to MEK inhibitors, 78 were treated with trametinib, 19 with cobimetinib, four with binimetinib, and 18 patients with two different MEK inhibitors at separate times. All grade digestive adverse events were observed in 39 (32.7%) patients. Grade 3 and 4 adverse events occurred in 6 (5%) patients: 2 (1.7%) developed perforations, 3 (2.5%) had colitis and 1 (0.8%) had grade 4 diarrhoea. These adverse events were all reversible following a permanent discontinuation of the MEK inhibitors, or a temporary interruption followed by resumption at a dose lower than conventional posology. There were no fatal outcomes; however one patient had a permanent ileostomy. The mechanism underlying these toxicities is not well known. Clinicians should be aware of such toxicities.
- Published
- 2019
28. Pédagogie à grande échelle en ACP
- Author
-
Séverine Valmary-Degano, Charlotte Gardair, Philippe Bertheau, Nicolas Poté, Caroline Eymerit-Morin, Joëlle Razafimahefa, Emmanuelle Uro-Coste, Martin Borduas, Jean-François Fléjou, Maxime Battistella, David Buob, Emmanuelle Leteurtre, Julien Calvani, Cécile Badoual, Rosemarie Tremblay-Le May, Anthony Jacquier, Emilie Perron, Thomas Denize, Université Paris Diderot - Paris 7 (UPD7), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Paris Descartes - Paris 5 (UPD5), CHU Saint-Antoine [AP-HP], Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 (JPArc), Université Lille Nord de France (COMUE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Toulouse (UT), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U1172 Inserm - U837 (JPArc), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Lille Nord de France (COMUE)-Université de Lille, CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université Fédérale Toulouse Midi-Pyrénées
- Subjects
0301 basic medicine ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,[SDV]Life Sciences [q-bio] ,Pathology and Forensic Medicine - Abstract
Resume L’enseignement de l’anatomie et cytologie pathologiques (ACP), au meme titre que l’enseignement des autres disciplines medicales, est a un tournant de son evolution. Face a une augmentation du champ des connaissances et de la complexite des diagnostics, l’epoque est a une mutualisation des ressources pedagogiques a une echelle regionale voire nationale. Nous presentons, ici, les outils en ligne permettant a des communautes d’etudiants de plus en plus larges d’acceder a des contenus d’apprentissage, a des auto-evaluations et a des outils d’evaluation de leurs competences. Les plateformes de e-learning et de MOOC (« Massive open online courses »), sont au centre de ces modalites pedagogiques, avec une mention particuliere pour la plateforme nationale des disciplines dediee a l’enseignement des 50 000 internes en medecine de France. Ces enseignements jouent aussi sur l’attractivite avec notamment les serious games, et on parlera de la place essentielle des images et des lames virtuelles dans l’enseignement de l’ACP. La pedagogie a grande echelle ne doit, bien sur, pas se concevoir comme un remplacement des enseignements utilises auparavant, mais comme l’etape initiale d’acquisition des connaissances, devant deboucher sur des enseignements presentiels renoves, centres sur l’interactivite et les competences.
- Published
- 2019
29. PAPASH, PsAPASH and PASS autoinflammatory syndromes: phenotypic heterogeneity, common biological signature and response to immunosuppressive regimens
- Author
-
G Hickman, Philippe Bertheau, Asma Smahi, P Claudepierre, P. Schneider, P Wolkenstein, C. Baudry, Marine Madrange, Hervé Bachelez, Pascal Richette, C. Gardair, E Sbidian, A. Frazier, and J. Gottlieb
- Subjects
Adult ,Male ,Adolescent ,Treatment outcome ,DNA Mutational Analysis ,Dermatology ,Saccharomyces cerevisiae ,Genetic Heterogeneity ,Young Adult ,Acne Vulgaris ,medicine ,Humans ,Spondylitis, Ankylosing ,Genetic Testing ,Age of Onset ,Antibodies, Fungal ,Genetic testing ,Arthritis, Infectious ,medicine.diagnostic_test ,business.industry ,Genetic heterogeneity ,Arthritis, Psoriatic ,Hereditary Autoinflammatory Diseases ,Syndrome ,Pyoderma Gangrenosum ,Hidradenitis Suppurativa ,Phenotype ,Treatment Outcome ,Immunology ,Female ,business ,Immunosuppressive Agents - Published
- 2019
30. [Large bowel ganglioneuromatosis associated with neurofibromatosis type 1]
- Author
-
Alice, Kieny, Claire, Auzolle, Philippe, Bertheau, and Maxime, Battistella
- Subjects
Male ,Incidental Findings ,Neurofibromatosis 1 ,Colonic Neoplasms ,Colonic Polyps ,Humans ,Ganglioneuroma ,Aged - Abstract
Gastrointestinal tract ganglioneuromatosis is a rare condition, which is isolated or included in a syndromique disease. Multiple endocrine neoplasia type 2 is the most frequently associated syndrome. Association with type 1 neurofibromatosis has also been established, but much rarely. We report the case of large bowel ganglioneuromatosis found incidentally in a patient with type 1 neurofibromatosis.
- Published
- 2018
31. [Large scale teaching in pathology]
- Author
-
Philippe, Bertheau, Thomas, Denize, Julien, Calvani, Charlotte, Gardair, Anthony, Jacquier, Joëlle, Razafimahefa, Caroline, Eymerit-Morin, Émilie, Perron, Rosemarie, Tremblay-Le May, Martin, Borduas, Nicolas, Pote, Maxime, Battistella, Cécile, Badoual, Jean-François, Fléjou, Emmanuelle, Leteurtre, Emmanuelle, Uro-Coste, David, Buob, and Séverine, Valmary-Degano
- Subjects
Education, Distance ,Pathology, Clinical ,Education, Medical, Graduate ,France - Abstract
Medical education is currently facing great changes that affect all medical specialties, including anatomical pathology. Due to rapidly increasing medical knowledge and diagnostic complexity, we are living an era of teaching resources mutualization. We present different tools that allow large numbers of students to access courses, self-evaluations, and competencies assessments. MOOC platforms and e-learning platforms are central to these new online tools, which include the French National Platform of Medical Specialties, dedicated to the teaching of 50,000 medical residents in France. We also discuss "serious games" and the use of images and virtual slides in anatomical pathology teaching. These new modalities can deliver essential knowledge to large student populations, but they must be used in conjunction with adapted teacher-led courses focusing on competencies and professional skills in order to be fully effective.
- Published
- 2018
32. Les coulisses d’un Massive Open Online Course (MOOC) sur le diagnostic des cancers
- Author
-
Jacqueline Lehmann-Che, Karima Sekri, Maxime Battistella, Cédric de Bazelaire, Julien Calvani, Laurent Prévaut, Jocelyne Gervais, Philippe Bertheau, Charlotte Gardair, Yohann Pottier, Guilhem Bousquet, Marie Sockeel, Patricia de Cremoux, and Jeanne Tran Van Nhieu
- Subjects
03 medical and health sciences ,0302 clinical medicine ,020205 medical informatics ,030220 oncology & carcinogenesis ,media_common.quotation_subject ,0202 electrical engineering, electronic engineering, information engineering ,02 engineering and technology ,Art ,Humanities ,Pathology and Forensic Medicine ,media_common - Abstract
Resume Le cours en ligne ouvert et massif (Massive Open Online Course ou MOOC) est une nouvelle modalite pedagogique en ligne s’adressant a une audience dont la taille est sans precedent par rapport aux autres strategies d’enseignement tout en permettant des interactions avec une equipe pedagogique. Ces cours universitaires, le plus souvent encore gratuits, donnent lieu a la remise d’une attestation de suivi et pourraient rapidement etre diplomants. Le MOOC « Strategies diagnostiques des cancers » sera dispense a l’automne 2016 sur la plateforme France universite numerique et aura deux niveaux d’apprenants : les etudiants de premier cycle dans le domaine de la sante et de la biologie et le grand public. Il sera egalement integre a des unites d’enseignement pour des etudiants en medecine des universites Paris Diderot et Paris 13. L’objectif pedagogique de ce MOOC est de transmettre a l’ensemble des apprenants une vision globale des etapes diagnostiques du cancer et des differentes specialites medicales impliquees dans ce diagnostic. La deuxieme semaine d’enseignement de ce MOOC, intitulee « le prelevement tumoral, son analyse macroscopique et microscopique », presente la specialite d’anatomie et cytologie pathologiques avec la prise en charge technique des echantillons tissulaires ou cellulaires et les elements basiques du raisonnement anatomopathologique. A l’issue de ce MOOC, il est prevu de realiser une evaluation de l’impact de cette nouvelle modalite d’enseignement sur la perception de l’anatomie et cytologie pathologiques par le grand public.
- Published
- 2016
33. Diagnostic du carcinome canalaire in situ : 3 recommandations nationales françaises
- Author
-
Marie-Pierre Chauvet, Luc Ceugnart, A. Lesur, Stéphanie Besnard, Christophe Hennequin, Bruno Cutuli, Alain Fourquet, Antoine Arnaud, Patricia de Cremoux, Audrey Lesieur, Philippe Bertheau, Christine Tunon de Lara, Charles Coutant, Véronique Boute, Chantal Belorgey, Anne Vincent-Salomon, Laurent Lévy, and L. Boulanger
- Subjects
Gynecology ,03 medical and health sciences ,medicine.medical_specialty ,Low-Grade DCIS ,0302 clinical medicine ,business.industry ,030220 oncology & carcinogenesis ,medicine ,Ductal carcinoma ,business ,030218 nuclear medicine & medical imaging ,Pathology and Forensic Medicine - Abstract
Resume Objectif Depuis les dernieres recommandations nationales elaborees par l’Institut national du cancer (INCa) et la Societe francaise de senologie et de pathologie mammaire (SFSPM) sur l’ensemble de la prise en charge diagnostique et therapeutique des carcinomes canalaires in situ (CCIS), de nouvelles publications ont fait emerger des interrogations en termes de bonnes pratiques et sur les possibilites de desescalade therapeutique dans la prise en charge des CCIS. L’actualisation de ces recommandations intervient dans un contexte de questionnement sur le surdiagnostic et son corollaire le surtraitement. Elle met a la disposition des professionnels des informations sur les bonnes pratiques correspondant a l’etat le plus recent des connaissances scientifiques et etudie notamment les possibilites de desescalade therapeutique. Methode Le processus d’elaboration est base sur une revue systematique de la litterature et sur le jugement argumente d’experts cliniciens au sein d’un groupe de travail multidisciplinaire. Avant publication, les recommandations sont revues par plus de cent experts cliniciens independants du groupe de travail. Resultats Cet article presente les recommandations nationales relatives a l’indication de l’IRM, la place de la macrobiopsie en cas de microcalcifications et la conduite a tenir en cas de CCIS de bas grade identifie par biopsie, dans le diagnostic des CCIS.
- Published
- 2016
34. Anti-PD1-induced collagenous colitis in a melanoma patient
- Author
-
Martine Bagot, Barouyr Baroudjian, Céleste Lebbé, Nelson Lourenco, Marianne Maillet, Philippe Bertheau, Matthieu Allez, Cécile Pagès, Ichrak Chami, and Jean-Marc Gornet
- Subjects
Budesonide ,Cancer Research ,medicine.medical_specialty ,Skin Neoplasms ,medicine.medical_treatment ,Colitis, Collagenous ,Programmed Cell Death 1 Receptor ,Ipilimumab ,Dermatology ,Pembrolizumab ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Colitis ,Melanoma ,Protein Kinase Inhibitors ,Aged ,Collagenous colitis ,business.industry ,Immunotherapy ,medicine.disease ,Regimen ,Oncology ,030220 oncology & carcinogenesis ,Female ,030211 gastroenterology & hepatology ,business ,medicine.drug - Abstract
Targeted immunotherapy has markedly improved the survival of melanoma patients. We report the case of a melanoma patient who developed a collagenous colitis under an anti-PD1 regimen. A 68-year-old woman was treated for a stage IV melanoma. An anti-PD1, pembrolizumab, was introduced after the failure of a first-line therapy with an anti-CTLA4. At cycle 14, pembrolizumab was interrupted because of grade 3 diarrhea. Histologic analysis of colon mucosa showed a thickened apical subepithelial collagen layer with irregular collagen deposition of more than 25 µm thickness. Budesonide 9 mg/day and cholestyramin 8 g/day were then introduced, leading to a decrease in the number of stools to grade 2. Because of the prognosis of the disease, the efficacy of pembrolizumab in this patient and the lack of other efficient treatments, pembrolizumab was restarted, with no worsening of the diarrhea after a follow-up of 8 weeks. In the era of immunotherapy, a new type of drug-induced colitis has emerged because of monoclonal antibodies targeting immune checkpoints such as CTLA-4 and PD1. Gastrointestinal tract immune-mediated adverse effects are now well described with ipilimumab. To the best of our knowledge, this is the first report of a collagenous colitis in a patient treated with pembrolizumab, thus suggesting a new mechanism of toxicity. Classically, collagenous colitis first-line treatment is based on discontinuation of the suspected treatment. However, there may be a strong benefit to maintaining an anti-PD1 regimen in our patients. In this case, symptomatic management associated with budesonide and cholestyramin enabled continuation of pembrolizumab.
- Published
- 2016
35. Masse pseudo-tumorale du sillon inter-duodéno-pancréatique
- Author
-
Nene Mbanzulu, Kouame-Justin Ndah, Fatiha Bouhidel, Brigitte Roche, Philippe Bertheau, and Maggy Grossin
- Subjects
03 medical and health sciences ,0302 clinical medicine ,Text mining ,business.industry ,030220 oncology & carcinogenesis ,Medicine ,Anatomy ,business ,030218 nuclear medicine & medical imaging ,Pathology and Forensic Medicine - Published
- 2016
36. COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients
- Author
-
Sylvie Giacchetti, Jacqueline Lehmann-Che, Ivan Bièche, Jean Marc Guinebretière, Philippe Bertheau, Bernard Asselain, Frédérique Spyratos, Patricia de Cremoux, Marie-Christine Mathieu, Jean-Yves Pierga, Véronique Scott, Michel Marty, Anne-Sophie Hamy, B Sigal, and Etienne Brain
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,macromolecular substances ,03 medical and health sciences ,Breast cancer ,Internal medicine ,Progesterone receptor ,Gene expression ,medicine ,skin and connective tissue diseases ,Prospective cohort study ,Neoadjuvant therapy ,030102 biochemistry & molecular biology ,business.industry ,food and beverages ,General Medicine ,medicine.disease ,Real-time polymerase chain reaction ,Predictive value of tests ,Celecoxib ,business ,medicine.drug - Abstract
BACKGROUND The prognostic and predictive role of cyclo-oxygenase-2 (COX2) in breast cancer is still debated, and in particular, its role as a target of COX2 inhibitor (celecoxib) in neoadjuvant setting. MATERIALS AND METHODS We analyzed a series of 156 breast cancer samples from patients of the COX2 inhibitor-treated arm included in the REMAGUS-02 randomized phase II trial. COX2 gene expression was assessed by reverse transcription and quantitative polymerase chain reaction using ribonucleic acid from frozen biopsies. Pathological complete response (pCR) was the surrogate end-point. RESULTS Significantly higher rates of grade 3, and estrogen and progesterone receptor negativity were observed in tumors with the highest expression of COX2. pCR rates were significantly higher in COX2-overexpressing tumors in patients receiving celecoxib. The test for interaction between COX2 gene expression and the celecoxib effect was statistically significant (p
- Published
- 2018
37. [A misleading breast metastasis of medullary thyroid carcinoma]
- Author
-
Charlotte, Gardair, Philippe, Drabent, Patrick, Charveriat, Philippe, Bertheau, Laurence, Cahen-Doidy, and Anne, de Roquancourt
- Subjects
Humans ,Breast Neoplasms ,Female ,Thyroid Neoplasms ,Middle Aged ,Carcinoma, Neuroendocrine - Abstract
Recognition of mammary metastases by pathologists is fundamental because their prognosis and treatment are different from those of primary mammary carcinomas. We report the case of a 54-year-old woman presenting on her mammography a left breast nodule known for 5 years, having discreetly increased in size. Breast ultrasound showed a regular 1.2cm hypoechogenic nodular formation. A microbiopsy was performed. On microscopic examination, we observed a tumor proliferation realizing nests within a small, richly vascularized stroma. The tumor cells had a moderately abundant, eosinophilic, granular cytoplasm and a rounded, slightly atypical nucleus. One mitosis was found for 10 fields at×400 magnification. Tumor cells did not express hormone receptors but chromogranin A, synaptophysin, TTF1 and thyrocalcitonin. The proliferation index established by the anti-Ki67 antibody was 5 %. The diagnosis was a secondary localization of a well-differentiated neuroendocrine tumor which immunohistochemical profile firstly suggests a thyroid origin. We later learned that the patient had a history of total thyroidectomy 13 years ago. It was a sporadic medullary carcinoma of the thyroid. Bone scintigraphy revealed a lacunar lesion of the posterior part of the right iliac wing suspicious of secondary location. This right iliac lesion was biopsied. It was also a localization of the medullary thyroid carcinoma. The final diagnosis is a metastatic medullary thyroid carcinoma, slowly progressive, the mammary metastasis having probably existed for 5 years.
- Published
- 2018
38. Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer
- Author
-
Christos Sotiriou, Pascal Merlet, Marc Espié, Luis Augusto Teixeira, Jacqueline Lehmann-Che, Lucie Biard, Philippe Bertheau, David Groheux, Matthieu Resche-Rigon, P. de Cremoux, Fatiha Bouhidel, and Brigitte Poirot
- Subjects
Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Triple Negative Breast Neoplasms ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Fluorodeoxyglucose F18 ,Internal medicine ,Positron Emission Tomography Computed Tomography ,Biopsy ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Pathological ,Neoadjuvant therapy ,Triple-negative breast cancer ,Cell Proliferation ,Retrospective Studies ,Chemotherapy ,medicine.diagnostic_test ,business.industry ,Retrospective cohort study ,General Medicine ,Genomics ,medicine.disease ,Neoadjuvant Therapy ,Treatment Outcome ,Positron emission tomography ,030220 oncology & carcinogenesis ,Positron-Emission Tomography ,Radiopharmaceuticals ,business ,Tomography, X-Ray Computed - Abstract
Survival is increased when pathological complete response (pCR) is reached after neoadjuvant chemotherapy (NAC), especially in triple-negative breast cancer (TNBC) patients. Positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (FDG) and the genomic grade index (GGI), each separately, showed good potential to predict pCR. Our study was designed to evaluate the predictive value for the therapeutic response of a combination of parameters based on FDG-PET, histoclinical features and molecular markers of proliferation. Molecular parameters were measured on pre-treatment biopsy. Tumor metabolic activity was measured using two PET/CT scans, one before and one after 2 cycles of NAC. The pCR was determined on specimen after NAC. Event-free survival (EFS) was estimated using the Kaplan Meier method. Of 55 TNBC patients, 19 (35%) reached pCR after NAC. Tumor grade and Ki67 were not associated with pCR whereas GGI (P = 0.04) and its component KPNA2 (P = 0.04) showed a predictive value. The change of FDG uptake between PET1 and PET2 (ΔSUVmax) was highly associated with pCR (P = 0.0001) but the absolute value of baseline SUVmax was not (P = 0.11). However, the AUC of pCR prediction increased from 0.63 to 0.76 when baseline SUVmax was combined with the GGI (P = 0.016). The only two parameters associated with EFS were ΔSUVmax (P = 0.048) and pathological response (P = 0.014). The early tumor metabolic change during NAC is a powerful parameter to predict pCR and outcome in TNBC patients. The GGI, determined on pretreatment biopsy, is also predictive of pCR and the combination GGI and baseline SUVmax improves the prediction.
- Published
- 2018
39. Toxicité digestive des MEK inhibiteurs au-delà des diarrhées banales
- Author
-
N. Lourenco, I. Madelaine, Barouyr Baroudjian, Philippe Bertheau, Clara Allayous, N. Mourad, C. Lebbé, Matthieu Allez, Julie Delyon, A. Ballon, Groupe Patio, and F. Herms
- Subjects
Dermatology - Abstract
Introduction Les inhibiteurs de MEK (MEKi) ont une toxicite digestive (TD) dose dependante exceptionnellement de grade 3. La frequence de la diarrhee est estimee a 40 % dans les essais cliniques, celle des vomissements a 10 %. Recemment des colites et des perforations digestives ont ete declarees a la pharmacovigilance, cependant la litterature sur ces complications est pauvre. Nous avons revu les TD de grades 3–4 survenues sous MEKi chez tous patients traites pour melanome stades III avance et IV dans notre centre. Materiel et methodes Analyse monocentrique a travers la base de donnees MelBase des dossiers des patients traites par MEKi seuls ou en association entre aout 2013 et mai 2018 et ayant developpe une ou plusieurs TD en utilisant les mots-cles : nausees, vomissements, diarrhee, douleur abdominale, colite, occlusion, perforation. Seules les TD gradees CTCAE 3 et 4 ont ete retenues. Resultats Parmi les 84 patients chez qui un MEKi avait ete introduit sur la periode analysee, 5 âges entre 41 et 76 ans developpaient des TD de grades 3 et 4 : 2 cas de perforation intestinale, 2 cas de colite et 1 cas de diarrhee febrile grade 4. Ces TD etaient notees sous cobimetinib (n = 2), trametinib (n = 2) et binimetinib (n = 1), et etaient apparues dans des delais allant d’une semaine a 5,5 mois de l’initiation du MEKi (mediane = 18 jours). Une des perforations survenait 5,5 mois apres introduction de cobimetinib. L’histologie montrait une reactivation d’une rectocolite hemorragique, qui etait quiescente depuis 15 ans sous mesalazine. L’autre perforation survenait une semaine apres initiation de trametinib ; l’histologie montrait une diverticulite sigmoidienne perforee avec peritonite aigue. Les 2 patients etaient operes en urgence avec realisation d’une derivation digestive. Les 2 cas de colite sous MEKi se declaraient par des diarrhees liquidiennes persistantes. La coloscopie montrait des ulcerations d’etendue variable. L’histologie montrait une colite ulceree possiblement medicamenteuse chez une patiente, et des remaniements inflammatoires vasculo-exsudatifs non granulomateux chez l’autre. L’evolution etait rapidement favorable a l’arret du traitement. Une des 2 patientes avait un antecedent de colite sous ipilimumab 17 mois auparavant. Enfin, une patiente developpait une reaction inflammatoire systemique severe avec diarrhee profuse 3 semaines apres initiation de trametinib. L’enquete infectieuse etait negative. L’evolution etait favorable apres un court sejour en reanimation, antibiotherapie et arret de la therapie ciblee. Les MEKi n’etaient pas repris ( Tableau 1 ). Conclusion Les MEKi sont connus pour avoir des TD, cependant celles de grades 3 et 4 sont mal decrites dans la litterature. Ces TD peuvent se declarer dans les quelques jours a quelques mois suivant l’introduction du traitement. Elles peuvent avoir des presentations variables allant d’une simple diarrhee a des perforations digestives.
- Published
- 2018
40. Syndromes PAPASH, PsAPASH et PASS : hétérogénéité phénotypique, signature biologique commune, intérêt des thérapeutiques immunosuppressives
- Author
-
G. Hickman, Philippe Bertheau, Pierre Wolkenstein, Marine Madrange, J. Gottlieb, Hervé Bachelez, P. Schneider, C. Gardair, Asma Smahi, Pascal Claudepierre, Pascal Richette, A. Frazier, C. Baudry, and Emilie Sbidian
- Subjects
Dermatology - Abstract
Introduction Les syndromes auto-inflammatoires (SAI) PAPASH, PsAPASH et PASS associent respectivement une spondylarthrite (Sp) peripherique, un rhumatisme psoriasique (RP) ou une Sp axiale a un pyoderma gangrenosum (PG), une acne, et une hidradenite suppuree (HS). Notre etude vise a preciser les phenotypes cutaneo-articulaires et les caracteristiques biologiques et therapeutiques de ces syndromes de description recente. Materiel et methodes Dans 2 centres experts, etude de cas sur les caracteristiques cliniques et biologiques incluant la recherche d’anticorps anti-saccharomyces cerevisiae (ASCA) ainsi que la reponse aux traitements. Une recherche de mutation des genes du complexe gamma-secretase (GS) APH1, NCSTN, PSENEN, PSTPIP1 et de NOD2 etait realisee. Resultats Neuf patients (4 hommes, 5 femmes) dont 2 PAPASH, 3 PASS, 1 PsAPASH et 3 patients avec une Sp mixte. L’âge moyen de debut de l’atteinte cutanee et/ou articulaire etait de 24,4 ans (14–40). L’HS etait constamment severe (Hurley III dans 8 cas), inaugurale (7), avec atteinte inguino-perineale et axillaire (9), ainsi qu’une acne cheloidienne de la nuque (3). La dermatose neutrophilique etait un PG (2), des pustules aseptiques disseminees (7), et/ou des abces aseptiques sous cutanes (2). L’asthenie constante etait parfois accompagnee de fievre (3). Le taux initial moyen de CRP etait de 82 mg/L, avec hypergammaglobulinemie (5/7) et SAA elevee (4/5). Les ASCA etaient positifs (7/8), sans signe endoscopique de maladie inflammatoire chronique intestinale (MICI) mais avec presence histologique d’abces ou d’infiltrat neutrophilique gastrique ou colique (3/5). Un patient presentait un RP, 3 une Sp axiale et peripherique, 3 une Sp axiale pure et 2 une atteinte peripherique seronegative. Aucune destruction articulaire n’etait observee. Aucune mutation n’etait trouvee. Les elements cutanes du syndrome dont l’HS resistaient a l’antibiotherapie, necessitant le recours aux immunomodulateurs (methotrexate, corticoides oraux, azathioprine, ciclosporine), tous en echec en monotherapie. Une reponse partielle a complete etait obtenue sous infliximab (jusqu’a 10 mg/kg/4 semaines) ou adalimumab (40 mg/semaine) combines a un autre immunomodulateur, avec des taux plasmatiques residuels d’anti-TNF souvent eleves. Discussion Les SAI PAPASH, PsAPASH et PASS sont severes par leur atteinte cutaneo-articulaire et systemique et partagent les ASCA comme biomarqueur commun, suggestif d’une dysbiose. Leur controle optimal est le plus souvent obtenu sous anti-TNF associe a un autre immunomodulateur, permettant parfois la chirurgie de l’HS. Conclusion Les SAI cutaneo-articulaires derives de l’HS, heterogenes sur le plan rhumatologique, sont particuliers par leur severite, par des marqueurs immunobiologiques communs et par la necessite d’un traitement immunosuppresseur intensif incluant un anti-TNF. Leur substratum genetique, inconnu, semble different de ceux de l’HS et d’autres SAI.
- Published
- 2018
41. Efficacité spectaculaire de l’infliximab au cours d’une colite aiguë grave au cours d’une nécrolyse épidermique toxique à la carbamazépine
- Author
-
Philippe Bertheau, J. Delaleu-Kossatikoff, A. Tournier, Marie Jachiet, J.-D. Bouaziz, Martine Bagot, J.-M. Gornet, and Clémence Lepelletier
- Subjects
Dermatology - Abstract
Introduction La necrolyse epidermique toxique (NET) est une toxidermie grave pouvant mettre en jeu le pronostic vital. L’atteinte cutaneomuqueuse est au premier plan, mais d’autres manifestations peuvent s’y associer. Observations Un patient de 26 ans etait suivi pour une epilepsie frontale focale non controlee pour laquelle un traitement par carbamazepine etait introduit. Dix jours plus tard apparaissait une eruption maculopapuleuse d’extension rapide avec secondairement decollement cutane et odynophagie. Au tableau cutane s’associaient simultanement des diarrhees glaireuses. Le patient etait transfere en reanimation devant une suspicion de NET a la carbamazepine, avec un score SCORTEN a 1. L’histologie cutanee et l’immunofluorescence directe negative confirmaient le diagnostic. L’evolution sur le plan cutaneomuqueux etait favorable apres arret de la carbamazepine et soins de support, mais les diarrhees devenaient glairo-sanglantes et plus frequentes (plus de 20 selles par jour). Le scanner abdominal montrait une ileite et une pancolite. Le bilan microbiologique etait negatif. La rectosigmoidoscopie trouvait une rectocolite ulceree sans intervalle de muqueuse saine. L’analyse histologique montrait d’importants remaniements inflammatoires de la muqueuse sigmoidienne compatibles avec des lesions de rectocolite hemorragique (RCH). Devant cette colite aigue grave, une corticotherapie systemique etait debutee a la dose de 1 mg/kg/j, sans efficacite ; apres une menace de perforation digestive, deux perfusion d’infliximab etaient effectuees a une semaine d’intervalle, respectivement de 5, et 10 mg/kg, permettant une remission clinique quasi complete en quelques jours, confirmee endoscopiquement. La cicatrisation cutanee et muqueuse etait complete ( Fig. 1 et 2 ). Discussion Une diarrhee chez un patient atteint de NET doit faire eliminer une cause infectieuse, mais une atteinte muqueuse colique specifique doit etre evoquee en cas de negativite des prelevements microbiologiques. Des atteintes coliques dans le cadre de NET sont parfois decrites comme evocatrices de RCH. Un cas similaire au cours d’un NET a la dapsone a precedemment ete decrit dans la litterature. Chez cette patiente, l’evolution sous soins de support nutritionnels avait ete defavorable (deces par perforation digestive). Chez notre patient, deux hypotheses sont possibles : une atteinte specifique de la NET « RCH-like » ou une poussee de RCH declenchee par la NET. Conclusion Nous rapportons le premier cas de colite aigue grave evocatrice de RCH concomitante a une NET a la carbamazepine d’evolution favorable apres deux perfusions d’anti-TNFα (infliximab). Devant une colite non infectieuse au cours d’une NET, la realisation d’une endoscopie digestive pour en preciser la nature doit etre discutee.
- Published
- 2018
42. Évaluation et valorisation lors de la conception innovante : vers un contrôle de gestion de l’immatériel adapté aux processus d’innovation
- Author
-
Philippe Bertheau, Claude Roche, and Nicolas Dufour
- Subjects
General Medicine - Published
- 2015
43. Déterminer la valeur de l’innovation en train de se faire, c’est aussi et déjà innover
- Author
-
Philippe Bertheau, Gilles Garel, Laboratoire interdisciplinaire de recherche en sciences de l'action (LIRSA), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université (HESAM)-HESAM Université (HESAM), and Bertheau, Philippe
- Subjects
knowledge ,intangibles ,Economics and Econometrics ,value ,innovative design ,intangibles,value,innovative design,knowledge,valeur,innovation,Conception,connaissances ,Strategy and Management ,valeur ,connaissances ,[SHS.GESTION]Humanities and Social Sciences/Business administration ,[SHS.GESTION] Humanities and Social Sciences/Business administration ,Conception ,innovation - Abstract
Research states that the success of a specific innovation cannot be predicted. As a consequence, the value of such an innovation can only be stated very late in the development process, or even in retrospect. Based on C-K design-theory, our empirical research shows that professionals directly engaged in the design process are able to perform an early and complete valuation. The cognitive process of this valuation is extremely similar to the overall process of innovative design. Also, this process has tangible outputs, in particular local, dedicated management tools used as proofs of concepts., La recherche en gestion a établi l'imprévisibilité du succès d'une innovation. Un corollaire largement accepté veut que la détermination de la valeur de cette innovation ne puisse être que tardive, voire rétrospective. Nous observons dans cette recherche que les acteurs directs de l'innovation sont à même de procéder à une détermination de la valeur précoce, complète et révisable. Nous appuyant sur la théorie C-K, nous montrons que ces équipes appliquent à la détermination de la valeur le même type de raisonnement qu'à l'innovation elle-même. Nous montrons également que ce travail de conception innovante passe par la génération d'outils de gestion locaux, souvent à l'usage exclusif du projet et utilisés pour mettre à l'épreuve les différents concepts de valeur.
- Published
- 2015
44. Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer
- Author
-
Jeanne Netter, Jacqueline Lehmann-Che, Jerome Lambert, Anne Tallet, Nelson Lourenco, Hany Soliman, Philippe Bertheau, Benjamin Pariente, Mircea Chirica, Marc Pocard, Matthieu Allez, Hugues De The, and Jean-Marc Gornet
- Subjects
Male ,Oncology ,Cancer Research ,Pathology ,Lung Neoplasms ,endocrine system diseases ,DNA Mutational Analysis ,Tp53 mutation ,Yeasts ,Antineoplastic Combined Chemotherapy Protocols ,Mutations TP53 ,Cytotoxicity ,Metastatic colon cancer ,education.field_of_study ,Pigmentation ,Liver Neoplasms ,TP53 mutation ,Hematology ,General Medicine ,Middle Aged ,Chemotherapy regimen ,3. Good health ,Radiology Nuclear Medicine and imaging ,Colonic Neoplasms ,Microsatellite Instability ,Réponse à la chimiothérapie ,medicine.drug ,Genetic Markers ,Proto-Oncogene Proteins B-raf ,medicine.medical_specialty ,Population ,Chemotherapy response ,Antineoplastic Agents ,Disease-Free Survival ,Proto-Oncogene Proteins p21(ras) ,Proto-Oncogene Proteins ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Gene Silencing ,Genetic Testing ,Progression-free survival ,education ,neoplasms ,Alleles ,Aged ,Retrospective Studies ,Analysis of Variance ,business.industry ,Carcinoma ,Wild type ,Genes, p53 ,Oxaliplatin ,Regimen ,Mutation ,ras Proteins ,Cancer colique metastatique ,business - Abstract
Summary Background Survival of metastatic colon cancer (mCC) patients has considerably improved with optimization of new drugs regimen. Inactivation of TP53 pathway by TP53 mutations is observed in nearly half of colorectal tumors. The impact of such mutations has been poorly studied in the metastatic setting. Methods The files of 254 mCC treated in a single institution at Saint-Louis hospital between January 1999 and April 2011 were retrospectively reviewed. Tissue samples for analysis of TP53 mutations were available for 68 patients, performed using FASAY. The prognostic value of TP53 status was evaluated by comparing progression free survival (PFS) and overall survival (OS) in the group of TP53-mutated and wild type patients. Results PFS was 6.9 months and OS 21.7 months in the whole population. There was no statistical difference in TP53- mutated and wild type groups in term of PFS (HR = 1.04; IC9 5% = 0.6–1.79) and OS (HR = 0.99; IC 95% = 0.53–1.55) whatever the chemotherapy regimen (oxaliplatin- or irinotecan-based). Only BRAF V600 mutation was demonstrated to be a poor prognostic factor for PFS and OS, and CEA level for OS. Conclusions Routine determination of TP53 mutations, even with a highly sensitive method, cannot be recommended to predict chemotherapy response in mCC.
- Published
- 2015
45. Une lésion inhabituelle de l’appendice
- Author
-
Fatiha Bouhidel, Brigitte Roche, Philippe Bertheau, Valère Belle Mbou, and Koffi Amegbor
- Subjects
Lesion ,medicine.anatomical_structure ,Text mining ,business.industry ,medicine ,Anatomy ,medicine.symptom ,business ,Appendix ,Pathology and Forensic Medicine - Published
- 2014
46. Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer
- Author
-
Marc Espié, Jean-Paul Feugeas, Philippe Bertheau, Anne Janin, Anne de Roquancourt, Tan Sophie, Laurence Verneuil, Christophe Leboeuf, Philippe Ratajczak, Morad El Bouchtaoui, Guilhem Bousquet, Cédric de Bazelaire, Sylvie Giacchetti, Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Hopital Saint-Louis [AP-HP] (AP-HP), Physiopathologie du système nerveux central - Institut François Magendie, Université Bordeaux Segalen - Bordeaux 2-IFR8-Institut National de la Santé et de la Recherche Médicale (INSERM), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Université Sorbonne Paris Cité (USPC), and leboeuf, Christophe
- Subjects
0301 basic medicine ,Oncology ,breast cancer stem cells ,medicine.medical_treatment ,Triple Negative Breast Neoplasms ,Mice ,0302 clinical medicine ,Medicine ,Prospective Studies ,Neoadjuvant therapy ,Triple-negative breast cancer ,chemoresistance ,Chloroquine ,Middle Aged ,Cell Hypoxia ,Neoadjuvant Therapy ,3. Good health ,030220 oncology & carcinogenesis ,Neoplastic Stem Cells ,Triple-Negative Breast Carcinoma ,Female ,TNBC ,Research Paper ,medicine.medical_specialty ,autophagy ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Antineoplastic Agents ,03 medical and health sciences ,Breast cancer ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Cancer stem cell ,Internal medicine ,Cell Line, Tumor ,Animals ,Humans ,Cell Proliferation ,Neoplasm Staging ,Chemotherapy ,business.industry ,hypoxia ,Cancer ,medicine.disease ,Xenograft Model Antitumor Assays ,030104 developmental biology ,Drug Resistance, Neoplasm ,Immunology ,Neoplasm Grading ,business - Abstract
// Guilhem Bousquet 1, 2, 3, 4 , Morad El Bouchtaoui 2 , Tan Sophie 2 , Christophe Leboeuf 1, 2 , Cedric de Bazelaire 1, 2, 5 , Philippe Ratajczak 1, 2 , Sylvie Giacchetti 6 , Anne de Roquancourt 1, 2, 7 , Philippe Bertheau 1, 2, 7 , Laurence Verneuil 1, 2 , Jean-Paul Feugeas 8 , Marc Espie 1, 6 , Anne Janin 1, 2, 7 1 Universite Paris Diderot, Sorbonne Paris Cite, Laboratoire Pathologie, Paris, France 2 INSERM, Paris, France 3 Universite Paris 13, Villetaneuse, France 4 AP, HP, Avicenne, Service Oncologie, Paris, France 5 AP HP Hopital Saint-Louis, Service Radiologie, Paris, France 6 AP HP Hopital Saint-Louis, Centre Maladies Sein, Paris, France 7 AP HP Hopital Saint-Louis, Service Pathologie, Paris, France 8 INSERM, Paris, France Correspondence to: Guilhem Bousquet, email: guilhem.bousquet@aphp.fr Anne Janin, email: anne.janin1165@gmail.com Keywords: breast cancer stem cells, TNBC, chemoresistance, autophagy, hypoxia Received: March 21, 2017 Accepted: March 29, 2017 Published: April 07, 2017 ABSTRACT There is growing evidence for the role of cancer stem-cells in drug resistance, but with few in situ studies on human tumor samples to decipher the mechanisms by which they resist anticancer agents. Triple negative breast cancer (TNBC) is the most severe sub-type of breast cancer, occurring in younger women and associated with poor prognosis even when treated at a localized stage. We investigated here the relationship between complete pathological response after chemotherapy and breast cancer stem-cell characteristics in pre-treatment biopsies of 78 women with triple negative breast carcinoma (TNBC). We found that chemoresistance was associated with large numbers of breast cancer stem-cells, and that these cancer stem-cells were neither proliferative nor apoptotic, but in an autophagic state related to hypoxia. Using relevant pharmacological models of patient-derived TNBC xenografts, we further investigated the role of autophagy in chemoresistance of breast cancer stem-cells. We demonstrated that hypoxia increased drug resistance of autophagic TNBC stem-cells, and showed that molecular or chemical inhibition of autophagic pathway was able to reverse chemoresistance. Our results support breast cancer stem-cell evaluation in pre-treatment biopsies of TNBC patients, and the need for further research on autophagy inhibition to reverse resistance to chemotherapy.
- Published
- 2017
47. [Results of the Massive Open Online Course (MOOC) on cancer diagnosis and evaluation of its impact on the perception of the pathology specialty]
- Author
-
Charlotte, Gardair, Guilhem, Bousquet, Cédric, de Bazelaire, Jaqueline, Lehmann-Che, Patricia, de Cremoux, Jeanne, Tran Van Nhieu, Maxime, Battistella, Marie, Sockeel, Julien, Calvani, Michel, Peuchmaur, Thierry, Molina, Jocelyne, Gervais, Emilie, Moenaert, Yohann, Pottier, Laurent, Prévaut, Karima, Sekri, and Philippe, Bertheau
- Subjects
Adult ,Education, Distance ,Male ,Pathology, Clinical ,Attitude ,Neoplasms ,Humans ,Female ,Computer-Assisted Instruction - Abstract
The Massive Open Online Course (or MOOC) "Diagnostic Strategies Cancers", was hosted in autumn 2016 on the platform "France Université Numérique" and had two levels of learners: students in the field of health and biology and the general public. Of the 5285 learners in 81 different countries, 1237 (23%) were successfully certified. This MOOC was also integrated into the teaching program of medical students of Paris Diderot University and Paris 13 University. Using anonymous questionnaires before and after MOOC, it has been shown that pathology is less known than other medical specialties. Participation in this MOOC led to a marked improvement in participants' knowledge of the place and role of the pathologist in the diagnosis of cancers. Regarding the students who have followed the MOOC as part of their university course, their comments were very positive, but it is necessary to make substantial adjustments in the amounts and contents of the campus-based courses.
- Published
- 2017
48. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status
- Author
-
Anne-Sophie Hamy, Fabien Reyal, Marc Espié, Brigitte Sigal-Zafrani, Philippe Bertheau, Michel Marty, Frédérique Berger, Marie-Christine Mathieu, Etienne Brain, Jean-Yves Pierga, Suzette Delaloge, Jean Marc Guinebretière, O Tembo, chafouny mazouni, Sylvie Giacchetti, Bernard Asselain, Florence Lerebours, and Mahasti Saghatchian
- Subjects
0301 basic medicine ,Oncology ,Adult ,Cancer Research ,medicine.medical_specialty ,Cyclophosphamide ,Receptor, ErbB-2 ,medicine.medical_treatment ,Population ,Breast Neoplasms ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Trastuzumab ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,skin and connective tissue diseases ,education ,neoplasms ,Aged ,Epirubicin ,Chemotherapy ,education.field_of_study ,business.industry ,Middle Aged ,medicine.disease ,030104 developmental biology ,Treatment Outcome ,Docetaxel ,Celecoxib ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Female ,business ,medicine.drug - Abstract
Background The REMAGUS-02 multicenter randomised phase II trial showed that the addition to neoadjuvant chemotherapy (NAC) of trastuzumab in patients with localised HER2-positive breast cancer (BC) increased the pathological complete response (pCR) rate and that the addition of celecoxib in HER2-negative cases did not increase the pCR rate. We report here the long-term follow-up results for disease-free survival (DFS) and overall survival (OS). Patients and methods From 2004 to 2007, 340 stage II–III BC patients were randomly assigned to receive neoadjuvant EC-T (four cycles of epirubicin–cyclophosphamide followed by four cycles of docetaxel) +/− celecoxib in HER2-negative cases (n = 220) and ± trastuzumab in HER2-positive cases (n = 120). From September 2005, all patients with HER2-positive BC received adjuvant T (n = 106). Results Median follow-up was nearly 8 years (94.4 months, 20–127 m). In the HER2-negative subgroup, addition of celecoxib was not associated with a DFS benefit. Favourable factors were smaller tumour size, expression of progesterone receptor status (PgR) and pCR. In the HER2-positive population, neoadjuvant trastuzumab was not associated with a DFS benefit. Axillary pCR was the only prognostic factor associated with DFS in this group [HR = 0.44, 95% CI = 0.2–0.97], p = 0.035]. To note, DFS and OS were significantly higher in the HER2-positive than in HER2-negative BC patients (HR = 0.58 [0.36–0.92], p = 0.021). Conclusion Celecoxib combined with NAC provided neither pCR nor survival benefit in patients with HER2-negative BC. Absence of PgR is a major prognostic factor. Neoadjuvant trastuzumab increased pCR rates without translation into a DFS or OS benefit compared with adjuvant trastuzumab only. Axillary pCR could be a more relevant surrogate of survival than in the breast in HER2-positive population. A retrospective comparison shows that patients with HER2-positive tumours have a better outcome than HER2-negative BC patients showing the impact of trastuzumab on the natural history of BC.
- Published
- 2016
49. Un important épaississement pariétal pylorique chez un adulte
- Author
-
Valère Belle Mbou, Franck Loiseaux, Philippe Bertheau, Brigitte Roche, and Fatiha Bouhidel
- Subjects
Gynecology ,medicine.medical_specialty ,Text mining ,business.industry ,medicine ,business ,Pathology and Forensic Medicine - Published
- 2015
50. Le portail pédagogique inter-universitaire en anatomie et cytologie pathologiques : un outil collaboratif national pour l’enseignement en ligne
- Author
-
Béatrice Vergier, Valérie Rigau, David Ameisen, Philippe Bertheau, Maxime Battistella, Jean Boutonnat, autres universités du réseau, Dominique Wendum, Christiane Copie, Françoise Galateau-Salle, Benoit Terris, Guillaume Gauchotte, and Stéphane Garcia
- Subjects
Political science ,Cooperative behavior ,Humanities ,Pathology and Forensic Medicine - Abstract
Resume La creation et la mise en ligne de materiel pedagogique demandent beaucoup de temps et d’energie, et restent difficile a organiser pour les enseignants d’une seule universite. Sous l’egide du College des pathologistes, nous avons initie la mise en place d’un reseau national inter-universitaire ayant pour objectif de creer et de mutualiser un enseignement en ligne en pathologie, reposant sur des cas anatomocliniques, des tests et d’autres contenus pedagogiques multimedias. Dix-neuf universites francaises sont associees a ce projet initialement soutenu par l’UNF3S ( http://www.unf3s.org/ ). Le contenu pedagogique en ligne repose sur une plate-forme utilisant le logiciel Moodle ( http://virtual-slides.univ-paris7.fr/moodle/ ), contenant du texte, differents medias et des liens vers des lames virtuelles decentralisees. Les enseignants ont appris a maitriser l’interface Moodle a l’aide de conferences Web avec partage d’ecran. A ce jour, 20 cas anatomocliniques ont ete crees, ainsi que plusieurs tests contenant des questions a choix multiples ou a reponses courtes, et des videos de macroscopie. Une enquete realisee aupres de 16 enseignants et etudiants a montre un taux de satisfaction de 94 %, la plupart souhaitant que ce type d’enseignement en ligne se developpe en complement de l’enseignement presentiel. Les developpements du site concerneront l’ensemble des niveaux d’etude, du L2–L3 jusqu’aux internes en pathologie et le developpement professionnel continu, en passant par la preparation aux ECN. En conclusion, ces nouveaux outils offrent de tres interessantes perspectives pour l’enseignement de la pathologie. L’organisation d’un reseau national inter-universitaire est un moyen efficace de creer et de mutualiser des ressources pedagogiques nombreuses et de qualite.
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.